Tauriga Sciences, Inc. is a healthcare company focused on developing and commercializing innovative drug products, particularly in the specialty and generic drug segments. The company's competitive position is bolstered by its proprietary formulations and a growing portfolio of cannabis-derived products, primarily targeting the North American market.
Business Overview
Tauriga generates revenue through the sale of its proprietary cannabis-derived formulations and generic drugs, leveraging its unique formulations to command higher prices. The company benefits from a favorable regulatory environment for cannabis products in North America, which enhances its pricing power and market penetration.
Regulatory changes affecting cannabis product legality and market access
Clinical trial results for new drug formulations
Partnerships or collaborations with larger pharmaceutical companies
Market demand for cannabis-derived products
Risk Factors
Regulatory changes in cannabis legislation that could restrict market access
Technological disruptions in drug development processes
Increased competition from larger pharmaceutical companies entering the cannabis space
Generic drug pricing pressures from competitors
High operating losses leading to potential liquidity issues
Dependence on external funding for R&D activities
Macro Sensitivity
moderate - The demand for healthcare products is somewhat insulated from economic cycles, but discretionary spending on wellness products can be affected by economic downturns.
Interest rates affect financing costs for R&D and operations, which can impact profitability and valuation multiples, particularly for a company with negative cash flow.
minimal - The company has a manageable debt-to-equity ratio of 0.45, indicating limited reliance on external credit.
Profile
growth - Investors are likely attracted to the potential for rapid revenue growth in the cannabis sector.
high - The stock has exhibited significant volatility, as evidenced by a 900% return over the past six months, indicating high investor sentiment and risk.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
